Physician profile
Martha Nicole Menefee
NPI 1336524461
$11,579.22
in general payments reported to CMS, 2019-2025
25 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 94% of Gerontology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $161).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,749 · 2022: $2,936 · 2023: $2,989 · 2024: $1,894 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,750.01 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,992.86 | 2021-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $1,803.48 | 2021-2025 | |
| Janssen Biotech, INC. | $1,578.18 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $969.49 | 2021-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $823.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $773.96 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $738.92 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.78 | 2021-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $552.14 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $532.09 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $318.31 | 2021-2025 | |
| Lilly USA, LLC | $154.04 | 2022-2024 | Taltz |
| Glaxosmithkline, LLC. | $149.35 | 2021-2025 | Benlysta, Nucala |
| Radius Health, INC. | $136.20 | 2021-2023 | Tymlos |
| Ani Pharmaceuticals, INC. | $66.95 | 2023-2025 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.46 | 2024 | Relistor |
| Alexion Pharmaceuticals, INC. | $44.91 | 2023-2025 | Strensiq |
| Organon LLC | $36.16 | 2024-2025 | Hadlima |
| Sandoz INC. | $31.72 | 2024-2025 | Jubbonti, Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $28.42 | 2023 | Opsumit |
| Biohaven Pharmaceuticals, INC. | $23.83 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.05 | 2021 | |
| Hikma Pharmaceuticals USA | $13.58 | 2023 | Kloxxado |
| Forte Bio-Pharma LLC | $13.51 | 2021 | |
| Grt US Holding, INC. | $7.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Menefee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.